JP
Therapeutic Areas
Alltrna Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AP003 | Arg-TGA (Arginine to TGA) Liver Stop Codon Disease (e.g., Methylmalonic Acidemia, Phenylketonuria, Organic Acidemias, Urea Cycle Disorders) | Pre-clinical |
| Gln-TAG Program | Gln-TAG (Glutamine to TAG) Liver Stop Codon Disease (e.g., Phenylketonuria, Organic Acidemias, Urea Cycle Disorders) | Discovery |
| Future Liver Programs | Other nonsense mutations causing Liver Stop Codon Disease | Discovery |
Leadership Team at Alltrna
MC
Michelle C. Werner
Chief Executive Officer
D(
David (Dave) Hava, Ph.D.
Chief Scientific Officer
NK
Nerissa Kreher, M.D.
Chief Medical Officer
CK
Caroline Köhrer, Ph.D.
Vice President, Discovery Platform
AP
Anne Pariser, M.D.
Vice President, Medical and Regulatory Affairs
CH
Chris Henderson, Ph.D.
Chairperson, Scientific Advisory Board (Former CSO)